gene therapy, Regeneron Pharmaceuticals and hearing loss
Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss
Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a mutation to the otoferlin gene. The company snapped up DB-OTO through its $109 million acquisition of Decibel Therapeutics in 2023.
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Hyderabad: Cell and gene therapy solutions provider Miltenyi Biotec on Monday announced the roll-out of what is touted as ...
Miltenyi Biotec launched India's first Cell and Gene Therapy Center in Hyderabad. The Miltenyi Innovation and Technology ...
Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback